Editas Medicine, Inc. (0IFK.L)
USD 0.97
(-7.8%)
USD 0.97
(-7.8%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 499.15 Million USD | -2.95% |
| 2022 | 514.32 Million USD | -24.08% |
| 2021 | 677.48 Million USD | 18.32% |
| 2020 | 572.6 Million USD | 12.52% |
| 2019 | 508.88 Million USD | 21.05% |
| 2018 | 420.38 Million USD | 12.63% |
| 2017 | 373.26 Million USD | 62.87% |
| 2016 | 229.18 Million USD | 53.44% |
| 2015 | 149.36 Million USD | 1125.49% |
| 2014 | 12.18 Million USD | 391.25% |
| 2013 | 2.48 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 384.8 Million USD | -12.61% |
| 2024 Q1 | 440.34 Million USD | -11.78% |
| 2024 Q3 | 327.56 Million USD | -14.87% |
| 2023 Q2 | 541.95 Million USD | 16.77% |
| 2023 Q3 | 504.65 Million USD | -6.88% |
| 2023 Q4 | 499.15 Million USD | -1.09% |
| 2023 FY | 499.15 Million USD | -2.95% |
| 2023 Q1 | 464.1 Million USD | -9.76% |
| 2022 FY | 514.32 Million USD | -24.08% |
| 2022 Q4 | 514.32 Million USD | -3.15% |
| 2022 Q3 | 531.02 Million USD | -8.57% |
| 2022 Q2 | 580.83 Million USD | -6.78% |
| 2022 Q1 | 623.1 Million USD | -8.03% |
| 2021 Q2 | 755.88 Million USD | -3.13% |
| 2021 Q1 | 780.29 Million USD | 36.27% |
| 2021 Q3 | 717.01 Million USD | -5.14% |
| 2021 Q4 | 677.48 Million USD | -5.51% |
| 2021 FY | 677.48 Million USD | 18.32% |
| 2020 Q1 | 466.73 Million USD | -8.28% |
| 2020 Q2 | 655.48 Million USD | 40.44% |
| 2020 Q3 | 597.15 Million USD | -8.9% |
| 2020 FY | 572.6 Million USD | 12.52% |
| 2020 Q4 | 572.6 Million USD | -4.11% |
| 2019 FY | 508.88 Million USD | 21.05% |
| 2019 Q3 | 372.35 Million USD | 4.71% |
| 2019 Q2 | 355.62 Million USD | -6.15% |
| 2019 Q1 | 378.91 Million USD | -9.86% |
| 2019 Q4 | 508.88 Million USD | 36.67% |
| 2018 Q2 | 393.53 Million USD | -2.59% |
| 2018 Q3 | 387.63 Million USD | -1.5% |
| 2018 FY | 420.38 Million USD | 12.63% |
| 2018 Q4 | 420.38 Million USD | 8.45% |
| 2018 Q1 | 403.98 Million USD | 8.23% |
| 2017 Q3 | 339.12 Million USD | -8.06% |
| 2017 FY | 373.26 Million USD | 62.87% |
| 2017 Q1 | 395.04 Million USD | 72.37% |
| 2017 Q2 | 368.84 Million USD | -6.63% |
| 2017 Q4 | 373.26 Million USD | 10.06% |
| 2016 Q3 | 242.15 Million USD | -2.98% |
| 2016 Q4 | 229.18 Million USD | -5.36% |
| 2016 Q2 | 249.6 Million USD | 0.32% |
| 2016 Q1 | 248.8 Million USD | 66.58% |
| 2016 FY | 229.18 Million USD | 53.44% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 149.36 Million USD | 1125.49% |
| 2015 Q4 | 149.36 Million USD | -6.5% |
| 2015 Q3 | 159.74 Million USD | 221.94% |
| 2015 Q2 | 49.61 Million USD | 0.0% |
| 2014 Q4 | 12.18 Million USD | 0.0% |
| 2014 FY | 12.18 Million USD | 391.25% |
| 2013 FY | 2.48 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 39.983% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 46.735% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 35.832% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -201.596% |
| bluebird bio, Inc. | 619.16 Million USD | 19.382% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -296.644% |
| Imunon, Inc. | 21.91 Million USD | -2177.358% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 98.129% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 85.125% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 58.359% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 84.648% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 64.573% |
| Verastem, Inc. | 149.71 Million USD | -233.395% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.384% |
| Waters Corporation | 4.62 Billion USD | 89.212% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.494% |
| Biogen Inc. | 26.84 Billion USD | 98.141% |
| Nektar Therapeutics | 398.03 Million USD | -25.405% |
| Perrigo Company plc | 10.8 Billion USD | 95.382% |
| Dynavax Technologies Corporation | 997.09 Million USD | 49.939% |
| Illumina, Inc. | 10.11 Billion USD | 95.063% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1665.514% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 36.035% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -124.332% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -659.861% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 92.704% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -201.931% |
| Evolus, Inc. | 188.99 Million USD | -164.105% |
| Adicet Bio, Inc. | 207.29 Million USD | -140.794% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -152.857% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.491% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -142.547% |
| FibroGen, Inc. | 423.52 Million USD | -17.856% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 95.362% |
| OPKO Health, Inc. | 2.01 Billion USD | 75.187% |
| Homology Medicines, Inc. | 47.05 Million USD | -960.741% |
| Geron Corporation | 394.07 Million USD | -26.664% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 86.967% |
| Exelixis, Inc. | 2.94 Billion USD | 83.036% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -35.459% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -223.315% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 61.632% |
| Zoetis Inc. | 14.28 Billion USD | 96.506% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 15.144% |
| Abeona Therapeutics Inc. | 64 Million USD | -679.902% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.804% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -792.157% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 83.306% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 84.71% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 19.688% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 71.202% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 52.428% |
| Insmed Incorporated | 1.32 Billion USD | 62.465% |
| TG Therapeutics, Inc. | 329.58 Million USD | -51.448% |
| Incyte Corporation | 6.78 Billion USD | 92.64% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 72.797% |